228 related articles for article (PubMed ID: 25766482)
1. CD14 expression is increased on monocytes in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis and correlates with the expression of ANCA autoantigens.
Tarzi RM; Liu J; Schneiter S; Hill NR; Page TH; Cook HT; Pusey CD; Woollard KJ
Clin Exp Immunol; 2015 Jul; 181(1):65-75. PubMed ID: 25766482
[TBL] [Abstract][Full Text] [Related]
2. Intermediate monocytes in ANCA vasculitis: increased surface expression of ANCA autoantigens and IL-1β secretion in response to anti-MPO antibodies.
O'Brien EC; Abdulahad WH; Rutgers A; Huitema MG; O'Reilly VP; Coughlan AM; Harrington M; Heeringa P; Little MA; Hickey FB
Sci Rep; 2015 Jul; 5():11888. PubMed ID: 26149790
[TBL] [Abstract][Full Text] [Related]
3. CX3CL1-induced CD16
Tang J; Liao Z; Luo L; Deng S; Jiang Y; Wang F; Hu X; Yin H; Gong G; Feng J; Li X
Front Immunol; 2022; 13():929244. PubMed ID: 36059489
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal immune cell monitoring identified CD14
Matsumoto K; Suzuki K; Yoshimoto K; Seki N; Tsujimoto H; Chiba K; Takeuchi T
Arthritis Res Ther; 2020 Jun; 22(1):145. PubMed ID: 32546274
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study.
Kim SM; Choi SY; Kim SY; Kim J
Rheumatol Int; 2019 Nov; 39(11):1919-1926. PubMed ID: 31552433
[TBL] [Abstract][Full Text] [Related]
6. Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wu EY; McInnis EA; Boyer-Suavet S; Mendoza CE; Aybar LT; Kennedy KB; Poulton CJ; Henderson CD; Hu Y; Hogan SL; Hu P; Xiao H; Nachman PH; Jennette JC; Falk RJ; Bunch DO
Arthritis Rheumatol; 2019 Nov; 71(11):1894-1903. PubMed ID: 31215772
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
[TBL] [Abstract][Full Text] [Related]
8. Clinical features and prognosis of ANCA-associated vasculitis patients who were double-seropositive for myeloperoxidase-ANCA and proteinase 3-ANCA.
Gong Y; Shen C; Meng T; Lin W; Hu X; Tang R; Xiong Q; Ooi JD; Eggenhuizen PJ; Chen J; Zhou YO; Luo H; Xu J; Liu N; Xiao P; Xiao X; Zhong Y
Clin Exp Med; 2024 Apr; 24(1):66. PubMed ID: 38564029
[TBL] [Abstract][Full Text] [Related]
9. Leucocyte membrane expression of proteinase 3 correlates with disease activity in patients with Wegener's granulomatosis.
Muller Kobold AC; Kallenberg CG; Tervaert JW
Br J Rheumatol; 1998 Aug; 37(8):901-7. PubMed ID: 9734683
[TBL] [Abstract][Full Text] [Related]
10. Increased circulating levels of proteinase 3 in patients with anti-neutrophilic cytoplasmic autoantibodies-associated systemic vasculitis in remission.
Ohlsson S; Wieslander J; Segelmark M
Clin Exp Immunol; 2003 Mar; 131(3):528-35. PubMed ID: 12605707
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of positive anti-neutrophil cytoplasmic antibodies without evidence of anti-neutrophil cytoplasmic antibodies-associated vasculitis.
Bornstein G; Ben-Zvi I; Furie N; Grossman C
Int J Rheum Dis; 2019 May; 22(5):940-945. PubMed ID: 30729688
[TBL] [Abstract][Full Text] [Related]
12. Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder D; Kabat B; Langford CA; Hoffman GS; Fervenza FC; Kallenberg CGM; Seo P; Spiera R; St Clair EW; Brunetta P; Stone JH; Merkel PA; Specks U; Monach PA;
Arthritis Rheumatol; 2018 Jul; 70(7):1114-1121. PubMed ID: 29693324
[TBL] [Abstract][Full Text] [Related]
13. The role of monocytes in ANCA-associated vasculitides.
Brunini F; Page TH; Gallieni M; Pusey CD
Autoimmun Rev; 2016 Nov; 15(11):1046-1053. PubMed ID: 27491570
[TBL] [Abstract][Full Text] [Related]
14. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
15. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
Berti A; Warner R; Johnson K; Cornec D; Schroeder DR; Kabat BF; Langford CA; Kallenberg CGM; Seo P; Spiera RF; St Clair EW; Fervenza FC; Stone JH; Monach PA; Specks U; Merkel PA;
J Autoimmun; 2019 Dec; 105():102302. PubMed ID: 31320177
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulins G from patients with ANCA-associated vasculitis are atypically glycosylated in both the Fc and Fab regions and the relation to disease activity.
Lardinois OM; Deterding LJ; Hess JJ; Poulton CJ; Henderson CD; Jennette JC; Nachman PH; Falk RJ
PLoS One; 2019; 14(2):e0213215. PubMed ID: 30818380
[TBL] [Abstract][Full Text] [Related]
17. Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
Murosaki T; Sato T; Akiyama Y; Nagatani K; Minota S
Mod Rheumatol; 2017 Jan; 27(1):95-101. PubMed ID: 27320904
[TBL] [Abstract][Full Text] [Related]
18. Disease Activity and Tendency to Relapse in ANCA-Associated Vasculitis Are Reflected in Neutrophil and Intermediate Monocyte Frequencies.
Smargianaki S; Elmér E; Lilliebladh S; Ohlsson S; Pettersson Å; Hellmark T; Johansson ÅC
J Immunol Res; 2024; 2024():6648265. PubMed ID: 38213873
[TBL] [Abstract][Full Text] [Related]
19. Antibody subtypes and titers predict clinical outcomes in ANCA-associated vasculitis.
Aljuhani M; Makati D; Hoff A; Thompson J; Pellegrino B; Shawwa K; Schmidt R; Kannabhiran D
Rheumatol Int; 2021 May; 41(5):965-972. PubMed ID: 33585954
[TBL] [Abstract][Full Text] [Related]
20. Incidence of PR3- and MPO-ANCA autoantibody specificity changes in ANCA-associated vasculitis.
Holding S; Fisher VJ; Abuzakouk M
Ann Clin Biochem; 2015 Mar; 52(Pt 2):297-301. PubMed ID: 24723621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
